These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 16507239)
21. New technologies and directed agents for applications of cancer imaging. Atri M J Clin Oncol; 2006 Jul; 24(20):3299-308. PubMed ID: 16829654 [TBL] [Abstract][Full Text] [Related]
22. Molecular and cellular targets of the MRI contrast agent P947 for atherosclerosis imaging. Ouimet T; Lancelot E; Hyafil F; Rienzo M; Deux F; Lemaître M; Duquesnoy S; Garot J; Roques BP; Michel JB; Corot C; Ballet S Mol Pharm; 2012 Apr; 9(4):850-61. PubMed ID: 22352457 [TBL] [Abstract][Full Text] [Related]
23. Biomarkers of atherosclerosis and the potential of MRI for the diagnosis of vulnerable plaque. Canet-Soulas E; Letourneur D MAGMA; 2007 Jun; 20(3):129-42. PubMed ID: 17605060 [TBL] [Abstract][Full Text] [Related]
24. Structural, functional, and molecular MR imaging of the microvasculature. Neeman M; Dafni H Annu Rev Biomed Eng; 2003; 5():29-56. PubMed ID: 14527310 [TBL] [Abstract][Full Text] [Related]
25. Novel MRI contrast agent for molecular imaging of fibrin: implications for detecting vulnerable plaques. Flacke S; Fischer S; Scott MJ; Fuhrhop RJ; Allen JS; McLean M; Winter P; Sicard GA; Gaffney PJ; Wickline SA; Lanza GM Circulation; 2001 Sep; 104(11):1280-5. PubMed ID: 11551880 [TBL] [Abstract][Full Text] [Related]
26. Molecular imaging of angiogenesis in nascent Vx-2 rabbit tumors using a novel alpha(nu)beta3-targeted nanoparticle and 1.5 tesla magnetic resonance imaging. Winter PM; Caruthers SD; Kassner A; Harris TD; Chinen LK; Allen JS; Lacy EK; Zhang H; Robertson JD; Wickline SA; Lanza GM Cancer Res; 2003 Sep; 63(18):5838-43. PubMed ID: 14522907 [TBL] [Abstract][Full Text] [Related]
28. Molecular imaging of atherosclerosis with nanoparticle-based fluorinated MRI contrast agents. Palekar RU; Jallouk AP; Lanza GM; Pan H; Wickline SA Nanomedicine (Lond); 2015; 10(11):1817-32. PubMed ID: 26080701 [TBL] [Abstract][Full Text] [Related]
29. MRI of tumor angiogenesis. Barrett T; Brechbiel M; Bernardo M; Choyke PL J Magn Reson Imaging; 2007 Aug; 26(2):235-49. PubMed ID: 17623889 [TBL] [Abstract][Full Text] [Related]
30. Histological validation of iron-oxide and gadolinium based MRI contrast agents in experimental atherosclerosis: the do's and don't's. den Adel B; Bovens SM; te Boekhorst B; Strijkers GJ; Poelmann RE; van der Weerd L; Pasterkamp G Atherosclerosis; 2012 Dec; 225(2):274-80. PubMed ID: 22882907 [TBL] [Abstract][Full Text] [Related]
32. Combined PET/DCE-MRI in a Rabbit Model of Atherosclerosis: Integrated Quantification of Plaque Inflammation, Permeability, and Burden During Treatment With a Leukotriene A4 Hydrolase Inhibitor. Calcagno C; Lairez O; Hawkins J; Kerr SW; Dugas MS; Simpson T; Epskamp J; Robson PM; Eldib M; Bander I; K-Raman P; Ramachandran S; Pruzan A; Kaufman A; Mani V; Ehlgen A; Niessen HG; Broadwater J; Fayad ZA JACC Cardiovasc Imaging; 2018 Feb; 11(2 Pt 2):291-301. PubMed ID: 29413439 [TBL] [Abstract][Full Text] [Related]
33. Contrast ultrasound imaging of the carotid artery vasa vasorum and atherosclerotic plaque neovascularization. Feinstein SB J Am Coll Cardiol; 2006 Jul; 48(2):236-43. PubMed ID: 16843169 [TBL] [Abstract][Full Text] [Related]
34. Multifunctional magnetic-gold nanoparticles for efficient combined targeted drug delivery and interstitial photothermal therapy. Elbialy NS; Fathy MM; Al-Wafi R; Darwesh R; Abdel-Dayem UA; Aldhahri M; Noorwali A; Al-Ghamdi AA Int J Pharm; 2019 Jan; 554():256-263. PubMed ID: 30423414 [TBL] [Abstract][Full Text] [Related]
35. Folate-targeting magnetic core-shell nanocarriers for selective drug release and imaging. Wang H; Wang S; Liao Z; Zhao P; Su W; Niu R; Chang J Int J Pharm; 2012 Jul; 430(1-2):342-9. PubMed ID: 22525087 [TBL] [Abstract][Full Text] [Related]
36. Targeted antiproliferative drug delivery to vascular smooth muscle cells with a magnetic resonance imaging nanoparticle contrast agent: implications for rational therapy of restenosis. Lanza GM; Yu X; Winter PM; Abendschein DR; Karukstis KK; Scott MJ; Chinen LK; Fuhrhop RW; Scherrer DE; Wickline SA Circulation; 2002 Nov; 106(22):2842-7. PubMed ID: 12451012 [TBL] [Abstract][Full Text] [Related]
37. Contrast-enhanced ultrasound imaging of the vasa vasorum: from early atherosclerosis to the identification of unstable plaques. Staub D; Schinkel AF; Coll B; Coli S; van der Steen AF; Reed JD; Krueger C; Thomenius KE; Adam D; Sijbrands EJ; ten Cate FJ; Feinstein SB JACC Cardiovasc Imaging; 2010 Jul; 3(7):761-71. PubMed ID: 20633855 [TBL] [Abstract][Full Text] [Related]
38. In vivo molecular imaging of acute and subacute thrombosis using a fibrin-binding magnetic resonance imaging contrast agent. Botnar RM; Perez AS; Witte S; Wiethoff AJ; Laredo J; Hamilton J; Quist W; Parsons EC; Vaidya A; Kolodziej A; Barrett JA; Graham PB; Weisskoff RM; Manning WJ; Johnstone MT Circulation; 2004 Apr; 109(16):2023-9. PubMed ID: 15066940 [TBL] [Abstract][Full Text] [Related]
40. Molecular Magnetic Resonance Imaging for the Detection of Vulnerable Plaques: Is It Possible?: Retracted. den Adel B; Daemen MJ; Poelmann RE; van der Weerd L Arterioscler Thromb Vasc Biol; 2013 Apr; ():. PubMed ID: 23413424 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]